

<b>MEDICAL POLICY</b>	<b>Percutaneous Ultrasonic Ablation for Tendinopathy</b>	
<b>Effective Date: 12/1/2020</b>   12/1/2020	Section: SUR	Policy No: 445
	Medical Policy Committee Approved Date: 10/19; 11/2020	
Medical Officer	Date	

**See Policy CPT/HCPCS CODE section below for any prior authorization requirements**

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Aycin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

All lines of business

**BENEFIT APPLICATION**

Medicaid Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**POLICY CRITERIA**

Percutaneous ultrasonic ablation for the treatment of tendinopathy (i.e., The Tenex Health TX® System) is considered **investigational and is not covered**.

Link to [Policy Summary](#)

**BILLING GUIDELINES**

If any of the following codes for tenotomy or fasciotomy are billed for percutaneous ultrasonic ablation, the code is considered investigational and is not covered:

- |       |       |          |
|-------|-------|----------|
| 24357 | 23405 | 28060    |
| 27306 | 23406 | 28230    |
| 27307 | 28008 | 28234-52 |

<b>MEDICAL POLICY</b>	<b>Percutaneous Ultrasonic Ablation for Tendinopathy</b>
-----------------------	--

27605	27005
27000	27006

**CPT/HCPCS CODES**

<b>All Lines of Business</b>	
<u>Note:</u> if a tenotomy of fasciotomy code is used to represent percutaneous ultrasonic ablation, the code is considered investigational and is not covered.	
<p><b>Unlisted Codes</b>  All unlisted codes will be reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is billed related to services addressed in this policy then it will be <b>denied as not covered</b>.</p>	
17999	Unlisted procedure, skin, mucous membrane and subcutaneous tissue
20999	Unlisted procedure, musculoskeletal system, general

**DESCRIPTION**

**Tendinopathy**

Tendinopathy is the breakdown of collagen in a tendon, what connects muscles to bones.<sup>1</sup> This breakdown causes pain, burning sensation, reduced flexibility, and decreased range of motion. Tendinopathy is most common in the following tendons: Achilles, rotator cuff, patellar, and hamstring.

Tendinopathy is most often due to overuse or sudden stress on a tendon. Aging and decreased muscle tone can also lead to the development of tendinopathy. Treatment of tendinopathy usually starts with rest, as well as ice, compress, and elevation. Physical therapy is also used to help rebuild strength and stimulate tendon healing. Surgery, tenotomy, is a last-line treatment in severe cases of tendinopathy.

**Percutaneous Ultrasonic Ablation (i.e., Tenex Health TX System)**

Percutaneous ultrasonic ablation using the Tenex Health TX System is intended as an alternative to conventional surgical techniques for the treatment of tendinopathy.<sup>2</sup> Tenex is an ultrasonic surgical instrument that breaks up hard and soft tissue. First, the TX System is used to visualize and identify the damaged tendon’s exact location via ultrasound imaging. The MicroTip needle of the Tenex device is then inserted under local anesthetic at the location of the damaged tissue. The ultrasonic treatment is then activated to break down and remove the damaged tissue. This minimally invasive, ultrasonic technique is purported to keep the surrounding tissue healthy and unharmed. The procedure can be performed on an outpatient basis, and recovery is estimated at four to six weeks.

## REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of percutaneous ultrasonic ablation (i.e., Tenex Health TX System) as a treatment of tendinopathy. Below is a summary of the available evidence identified through August of 2020.

In 2020, Hayes published an evidence analysis research brief on Tenex Health TX procedure for the treatment of tendinopathies. A publication search through February 2020 found 10 abstracts to review, none of which were randomized and only one of which was prospective. Hayes concluded that there is insufficient published evidence to assess the safety and efficacy of Tenex for the management of tendinopathies.<sup>3</sup>

In 2013 (updated 2019), the ECRI Institute conducted a systematic evidence review to evaluate the Tenex Health TX System (Tenex Health, Inc.) for Treating Chronic Tendinopathy.<sup>2</sup> The review identified six small studies (one retrospective nonrandomized study and five case series), encompassing 163 patients, evaluating Tenex for the treatment of tendinopathy. All studies were determined to be at a high risk of bias.

Two prospective case series (n=20, n=19) and one retrospective study (n=62) evaluated Tenex for the treatment of elbow tendinopathy. Both reported improved visual analog scale pain scores and Disabilities of the Arm, Shoulder, and Hand scores at 1-to-3-year follow-up. Two of the three studies also reported that over 80% of patients were satisfied with the treatment and less than 20% required additional treatment. The nonrandomized retrospective study reported similar outcomes for pain relieve and function with Tenex compared to platelet-rich plasma injections.

In regards to lower-limb tendinopathies, one retrospective case series (n=34) reported reduction in moderate to severe pain from 68% to 15% in patients with Achilles tendinopathy. Two prospective case series reported recovery to full function in 10/16 patients after Tenex treatment for patellar tendonitis. Additionally, 12/13 patients reported complete pain resolution after plantar fascia treatment.

The ECRI review concluded “(f)indings are at very high risk of bias from 3 or more of the following: lack of control group, randomization, and blinding; small sample size; retrospective design; and/or single center focus. The studies also reported subjective outcome measures (i.e., pain), which is why control groups, randomization, and blinding are needed to reduce bias.”<sup>2</sup> The ECRI Evidence Bar™ was determined to be “inconclusive” because of “too few data”.<sup>2</sup>

## CLINICAL PRACTICE GUIDELINES

No clinical practice guidelines were identified which address percutaneous ultrasonic ablation for tendinopathy.

## CENTERS FOR MEDICARE & MEDICAID

As of 9/23/2020, no Centers for Medicare & Medicaid (CMS) coverage guidance was identified which addresses percutaneous ultrasonic ablation for tendinopathy.

## POLICY SUMMARY

There is insufficient high-quality, published evidence to evaluate the safety, efficacy, and clinical utility of percutaneous ultrasonic ablation for tendinopathy. Larger, higher-quality studies (i.e., randomized controlled trials) are required to validate the findings of the current body of literature. Additional studies should also compare percutaneous ultrasonic ablation with other established surgical treatments of tendinopathy.

## INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days' notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

## REGULATORY STATUS

### U.S. Food and Drug Administration (FDA)

FDA granted 510(k) marketing clearance to for the Tenex Health TX System on March 3, 2016 (510(k) Number: K153299).<sup>4</sup> Indications for use:

*"The Tenex Health TX System is indicated for use in surgical procedures where fragmentation, emulsification and aspiration of soft tissue are desirable, including General Surgery, Orthopedic Surgery, Laparoscopic Surgery and Plastic and Reconstructive Surgery."*<sup>4</sup>

### Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

## REFERENCES

1. Morrison W. Healthline: Understanding Tendinopathy. Published 11/8/2018. <https://www.healthline.com/health/tendinopathy>. Accessed 9/23/2020.
2. ECRI Institute: Tenex Health TX System (Tenex Health, Inc.) for Treating Chronic Tendinopathy. <https://www.ecri.org/components/ProductBriefs/Pages/13597.aspx?tab=1>. Published 2013 (Updated 2019). Accessed 9/23/2020.

3. Hayes. Tenex Health TX Procedure (Tenex Health Inc.) For Treatment Of Tendinopathies. Published 2/26/2020. <https://evidence.hayesinc.com/report/hss.tenexhealth2605>. Accessed 9/23/2020.
4. U.S. Food and Drug Administration 510(k) Approval Letter: Tenex Health TX System. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf15/K153299.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153299.pdf). Published 2016. Accessed 9/23/2020.